United States Pharmaceuticals

Theravance Biopharma Inc (TBPH)

Track

Over the past 90 days, Theravance Biopharma Inc. has seen significant insider selling, totaling approximately $6.35 million in net value. Key transactions involved Eli Samaha and Rhonda Farnum, with no reported insider purchases. This activity follows a recent earnings report where the company missed EPS expectations by 88.89%.
Ticker: TBPH Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Theravance Biopharma Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Sale 7 Jul 2026
Value US$2,061,520.08 | Price 126.72 | Shares 4,516 (-9.9%)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-07-08 2026-07-07 S Sale
3.1
Samaha Eli
Large shareholder
4,516 -9.9%
126.72
US$2,061,520 		4,516 -9.9% 126.72 US$2,061,520
2026-07-08 2026-07-06 S Sale
3.1
Samaha Eli
Large shareholder
12,359 -48.0%
274.91
US$1,702,475 		12,359 -48.0% 274.91 US$1,702,475
2026-07-01 2026-07-01 S Sale
3.1
Samaha Eli
Large shareholder
55,495 -6.6%
374.00
US$3,943,815 		55,495 -6.6% 374.00 US$3,943,815
2026-07-01 2026-06-30 S Sale
3.1
Samaha Eli
Large shareholder
25,027 -0.3%
17.13
US$428,788 		25,027 -0.3% 17.13 US$428,788
2026-07-01 2026-06-29 S Sale
3.1
Samaha Eli
Large shareholder
273,871 -2.9%
17.23
US$4,720,139 		273,871 -2.9% 17.23 US$4,720,139
2026-06-17 2026-06-15 S Sale
2.6
Farnum Rhonda

SVP, COMM & MEDICAL AFFAIRS

Officer
6,657 -2.8%
16.39
US$109,079 		6,657 -2.8% 16.39 US$109,079
2026-06-17 2026-06-15 S Sale
2.6
Farnum Rhonda

SVP, COMM & MEDICAL AFFAIRS

Officer
3,328 -1.4%
16.38
US$54,525 		3,328 -1.4% 16.38 US$54,525
2026-06-17 2026-06-15 S Sale
2.6
Farnum Rhonda

SVP, COMM & MEDICAL AFFAIRS

Officer
3,329 -1.4%
16.39
US$54,563 		3,329 -1.4% 16.39 US$54,563
2026-06-15 2026-06-15 PrS Proposed sale
2.6
RHONDA FARNUM

Officer

Officer
13,314
16.39
US$218,167 		13,314 16.39 US$218,167
2026-03-18 2026-03-16 S Sale
2.6
Farnum Rhonda

SVP, COMM & MEDICAL AFFAIRS

Officer
7,766 -3.2%
13.92
US$108,073 		7,766 -3.2% 13.92 US$108,073
2026-03-18 2026-03-16 S Sale
2.6
Farnum Rhonda

SVP, COMM & MEDICAL AFFAIRS

Officer
15,534 -6.1%
14.00
US$217,476 		15,534 -6.1% 14.00 US$217,476
2026-03-18 2026-03-16 S Sale
2.6
Farnum Rhonda

SVP, COMM & MEDICAL AFFAIRS

Officer
7,767 -2.9%
13.92
US$108,088 		7,767 -2.9% 13.92 US$108,088
2026-03-16 2026-03-16 PrS Proposed sale
2.6
RHONDA FARNUM

Officer

Officer
31,067
13.96
US$433,637 		31,067 13.96 US$433,637
2025-12-05 2025-12-03 S Sale
2.6
Farnum Rhonda

SVP, COMM & MEDICAL AFFAIRS

Officer
15,534 -5.3%
18.75
US$291,252 		15,534 -5.3% 18.75 US$291,252
2025-12-05 2025-12-03 S Sale
2.6
Farnum Rhonda

SVP, COMM & MEDICAL AFFAIRS

Officer
7,766 -2.6%
18.75
US$145,619 		7,766 -2.6% 18.75 US$145,619
2025-12-05 2025-12-03 S Sale
2.6
Farnum Rhonda

SVP, COMM & MEDICAL AFFAIRS

Officer
7,767 -2.5%
18.75
US$145,630 		7,767 -2.5% 18.75 US$145,630
2025-12-03 2025-12-03 PrS Proposed sale
2.6
RHONDA FARNUM

Officer

Officer
31,067
18.75
US$582,500 		31,067 18.75 US$582,500
2025-12-01 2025-11-26 PlS Planned sale
1.7
BROSHY ERAN
Non-Executive Director
15,501 -25.7%
20.00
US$310,020 		15,501 -25.7% 20.00 US$310,020
2025-12-01 2025-11-26 PlS Planned sale
1.7
BROSHY ERAN
Non-Executive Director
14,000 -18.9%
20.00
US$280,000 		14,000 -18.9% 20.00 US$280,000
2025-11-26 2025-11-26 PrS Proposed sale
1.7
ERAN BROSHY

Director

Non-Executive Director
29,501
20.00
US$590,020 		29,501 20.00 US$590,020
2025-11-13 2025-11-11 PlS Planned sale
1.7
BROSHY ERAN
Non-Executive Director
14,000 -23.3%
18.50
US$259,000 		14,000 -23.3% 18.50 US$259,000
2025-11-13 2025-11-11 PlS Planned sale
1.7
BROSHY ERAN
Non-Executive Director
15,500 -25.1%
17.00
US$263,500 		15,500 -25.1% 17.00 US$263,500
2025-11-13 2025-11-11 PlS Planned sale
1.7
BROSHY ERAN
Non-Executive Director
29,500 -32.3%
18.50
US$545,750 		29,500 -32.3% 18.50 US$545,750
2025-11-12 2025-11-11 PrS Proposed sale
1.7
ERAN BROSHY

Director

Non-Executive Director
45,000
17.98
US$809,250 		45,000 17.98 US$809,250
2025-07-16 2025-07-14 S Sale
2.6
Farnum Rhonda

SVP, COMM & MEDICAL AFFAIRS

Officer
4,000 -1.2%
11.39
US$45,552 		4,000 -1.2% 11.39 US$45,552
2025-07-16 2025-07-14 S Sale
2.6
Farnum Rhonda

SVP, COMM & MEDICAL AFFAIRS

Officer
5,318 -1.6%
11.39
US$60,548 		5,318 -1.6% 11.39 US$60,548
2025-07-16 2025-07-14 S Sale
2.6
Farnum Rhonda

SVP, COMM & MEDICAL AFFAIRS

Officer
682 -0.2%
11.39
US$7,770 		682 -0.2% 11.39 US$7,770
2025-07-14 2025-07-14 PrS Proposed sale
2.6
RHONDA FARNUM

Officer

Officer
10,000
11.39
US$113,869 		10,000 11.39 US$113,869
2025-06-04 2025-06-02 S Sale
2.6
Farnum Rhonda

SVP, COMM & MEDICAL AFFAIRS

Officer
24,000 -6.6%
11.00
US$264,000 		24,000 -6.6% 11.00 US$264,000
2025-06-02 2025-06-02 PrS Proposed sale
2.6
RHONDA FARNUM

Officer

Officer
24,000
11.00
US$264,000 		24,000 11.00 US$264,000
2025-04-23 2025-04-21 S Sale
2.6
Farnum Rhonda

SVP, COMM & MEDICAL AFFAIRS

Officer
4,000 -1.1%
9.00
US$36,000 		4,000 -1.1% 9.00 US$36,000
2025-01-23 2025-01-21 S Sale
2.6
Farnum Rhonda

SVP, COMM & MEDICAL AFFAIRS

Officer
4,000 -1.3%
9.00
US$36,000 		4,000 -1.3% 9.00 US$36,000
2025-01-21 2025-01-21 PrS Proposed sale
2.6
RHONDA FARNUM

Officer

Officer
4,000
9.00
US$36,000 		4,000 9.00 US$36,000
2024-11-13 2024-11-11 S Sale
2.6
Farnum Rhonda

SVP, COMM & MEDICAL AFFAIRS

Officer
4,000 -1.2%
9.00
US$36,000 		4,000 -1.2% 9.00 US$36,000
2024-08-09 2024-08-07 B Purchase
3.1
Samaha Eli
Large shareholder
999,800 +11.7%
7.80
US$7,798,440 		999,800 +11.7% 7.80 US$7,798,440
2024-07-12 2024-07-10 PlS Planned sale
2.6
Farnum Rhonda

SVP, COMM & MEDICAL AFFAIRS

Officer
4,000 -1.2%
9.00
US$36,000 		4,000 -1.2% 9.00 US$36,000
2024-05-03 2024-05-01 B Purchase
3.1
Samaha Eli
Large shareholder
499,324 +6.2%
8.75
US$4,369,085 		499,324 +6.2% 8.75 US$4,369,085
2024-05-03 2024-05-01 B Purchase
3.1
Samaha Eli
Large shareholder
999,800 +14.3%
8.75
US$8,748,250 		999,800 +14.3% 8.75 US$8,748,250
2024-02-22 2024-02-22 PlS Planned sale
2.6
Farnum Rhonda

SVP, COMM & MEDICAL AFFAIRS

Officer
1,254 -0.4%
8.71
US$10,922 		1,254 -0.4% 8.71 US$10,922
2023-11-22 2023-11-21 PlS Planned sale
2.6
Farnum Rhonda

SVP, COMM & MEDICAL AFFAIRS

Officer
1,378 -0.4%
10.29
US$14,180 		1,378 -0.4% 10.29 US$14,180
2023-11-16 2023-11-14 PlS Planned sale
2.1
GRAHAM RICHARD A

SVP, RESEARCH & DEVELOPMENT

Officer
2,482 -0.7%
10.22
US$25,366 		2,482 -0.7% 10.22 US$25,366
2023-11-14 2023-11-14 PrS Proposed sale
2.1
RICHARD A GRAHAM

Officer

Officer
2,482
10.22
US$25,366 		2,482 10.22 US$25,366
2023-10-18 2023-10-16 PlS Planned sale
2.1
GRAHAM RICHARD A

SVP, RESEARCH & DEVELOPMENT

Officer
2,482 -0.7%
9.03
US$22,412 		2,482 -0.7% 9.03 US$22,412
2023-10-16 2023-10-16 PrS Proposed sale
2.1
RICHARD A GRAHAM

Officer

Officer
2,482
9.03
US$22,412 		2,482 9.03 US$22,412
2023-09-18 2023-09-14 PlS Planned sale
2.1
GRAHAM RICHARD A

SVP, RESEARCH & DEVELOPMENT

Officer
2,482 -0.7%
9.89
US$24,547 		2,482 -0.7% 9.89 US$24,547
2023-09-14 2023-09-14 PrS Proposed sale
2.1
RICHARD A GRAHAM

Officer

Officer
2,482
9.89
US$24,547 		2,482 9.89 US$24,547
2023-08-24 2023-08-22 PlS Planned sale
2.6
Farnum Rhonda

SVP, COMM & MEDICAL AFFAIRS

Officer
1,807 -0.5%
9.47
US$17,112 		1,807 -0.5% 9.47 US$17,112
2023-08-15 2023-08-11 PlS Planned sale
2.1
GRAHAM RICHARD A

SVP, RESEARCH & DEVELOPMENT

Officer
2,322 -0.7%
9.99
US$23,197 		2,322 -0.7% 9.99 US$23,197
2023-08-11 2023-08-11 PrS Proposed sale
2.1
RICHARD A GRAHAM

Officer

Officer
2,322
9.99
US$23,197 		2,322 9.99 US$23,197
2023-07-18 2023-07-14 PlS Planned sale
2.1
GRAHAM RICHARD A

SVP, RESEARCH & DEVELOPMENT

Officer
2,322 -0.7%
9.84
US$22,848 		2,322 -0.7% 9.84 US$22,848
2023-07-14 2023-07-14 PrS Proposed sale
2.1
RICHARD A GRAHAM

Officer

Officer
2,322
9.84
US$22,848 		2,322 9.84 US$22,848
2023-06-16 2023-06-14 PlS Planned sale
2.1
GRAHAM RICHARD A

SVP, RESEARCH & DEVELOPMENT

Officer
2,322 -0.7%
10.69
US$24,822 		2,322 -0.7% 10.69 US$24,822
2023-06-14 2023-06-14 PrS Proposed sale
2.1
RICHARD A GRAHAM

Officer

Officer
2,322
10.69
US$24,822 		2,322 10.69 US$24,822
2023-06-12 2023-06-08 PlS Planned sale
2.6
Farnum Rhonda

SVP, COMM & MEDICAL AFFAIRS

Officer
1,790 -0.5%
11.13
US$19,923 		1,790 -0.5% 11.13 US$19,923
2023-06-08 2023-06-08 PrS Proposed sale
2.6
RHONDA FARNUM

Officer

Officer
1,790
11.13
US$19,923 		1,790 11.13 US$19,923
2023-05-17 2023-05-15 PlS Planned sale
2.1
GRAHAM RICHARD A

SVP, RESEARCH & DEVELOPMENT

Officer
2,322 -0.6%
11.26
US$26,146 		2,322 -0.6% 11.26 US$26,146
2023-05-15 2023-05-15 PrS Proposed sale
2.1
RICHARD A GRAHAM

Officer

Officer
2,322
11.26
US$26,146 		2,322 11.26 US$26,146
2023-04-18 2023-04-14 PlS Planned sale
2.1
GRAHAM RICHARD A

SVP, RESEARCH & DEVELOPMENT

Officer
2,323 -0.6%
11.88
US$27,597 		2,323 -0.6% 11.88 US$27,597
2023-04-14 2023-04-14 PrS Proposed sale
2.1
RICHARD A GRAHAM

Officer

Officer
2,323
11.88
US$27,597 		2,323 11.88 US$27,597
2023-03-16 2023-03-14 PlS Planned sale
2.1
GRAHAM RICHARD A

SVP, RESEARCH & DEVELOPMENT

Officer
2,323 -0.6%
10.32
US$23,973 		2,323 -0.6% 10.32 US$23,973
2023-03-13 2023-03-09 S Sale
2.6
Farnum Rhonda

SVP, COMM & MEDICAL AFFAIRS

Officer
4,000 -1.1%
10.20
US$40,800 		4,000 -1.1% 10.20 US$40,800
2023-03-08 2023-03-06 PlS Planned sale
2.1
GRAHAM RICHARD A

SVP, RESEARCH & DEVELOPMENT

Officer
2,323 -0.6%
10.05
US$23,346 		2,323 -0.6% 10.05 US$23,346
2022-12-16 2022-12-14 S Sale
3.6
Winningham Rick E

CHIEF EXECUTIVE OFFICER

Executive Director
50,000 -3.6%
11.19
US$559,500 		50,000 -3.6% 11.19 US$559,500
2022-12-05 2022-12-01 S Sale
2.1
GRAHAM RICHARD A

SVP, RESEARCH & DEVELOPMENT

Officer
2,084 -0.7%
10.73
US$22,361 		2,084 -0.7% 10.73 US$22,361
2022-11-22 2022-11-18 S Sale
2.8
Hindman Andrew A.

SVP, CHIEF FINANCIAL OFFICER

Officer
65,000 -13.7%
11.02
US$716,242 		65,000 -13.7% 11.02 US$716,242
2022-08-18 2022-08-16 S Sale
2.1
GRAHAM RICHARD A

SVP, DEVELOPMENT

Officer
4,906 -1.3%
9.71
US$47,640 		4,906 -1.3% 9.71 US$47,640
2022-08-11 2022-08-09 S Sale
2.1
GRAHAM RICHARD A

SVP, DEVELOPMENT

Officer
15,086 -3.9%
8.79
US$132,606 		15,086 -3.9% 8.79 US$132,606
2022-05-24 2022-05-23 PlS Planned sale
2.6
Farnum Rhonda

SVP, COMM & MEDICAL AFFAIRS

Officer
1,081 -0.3%
8.93
US$9,653 		1,081 -0.3% 8.93 US$9,653
2022-03-02 2022-02-28 PlS Planned sale
2.6
Farnum Rhonda

SVP, COMM & MEDICAL AFFAIRS

Officer
2,356 -0.7%
10.16
US$23,947 		2,356 -0.7% 10.16 US$23,947
2021-03-11 2021-03-09 S Sale
2.9
WORBOYS PHILIP D

SVP, Research & Transl Science

Officer
8,829 -2.5%
20.00
US$176,580 		8,829 -2.5% 20.00 US$176,580
2020-12-16 2020-12-14 S Sale
2.1
GRAHAM RICHARD A

SVP, Development

Officer
7,500 -5.7%
19.47
US$146,058 		7,500 -5.7% 19.47 US$146,058
2020-12-07 2020-12-03 S Sale
2.9
WORBOYS PHILIP D

SVP, Research & Transl Science

Officer
4,246 -1.3%
18.00
US$76,428 		4,246 -1.3% 18.00 US$76,428
2020-08-24 2020-08-21 S Sale
2.3
HAUMANN BRETT K

Chief Medical Officer

Officer
25,000 -8.1%
18.29
US$457,240 		25,000 -8.1% 18.29 US$457,240
2020-08-24 2020-08-20 S Sale
2.9
WORBOYS PHILIP D

SVP, Research & Transl Science

Officer
17,103 -4.9%
18.00
US$307,854 		17,103 -4.9% 18.00 US$307,854
2019-12-16 2019-12-12 S Sale SABESAN VIJAY

SVP, Technical Operations

Officer
1,027 -0.7%
21.03
US$21,598 		1,027 -0.7% 21.03 US$21,598
Explore more

More insider trading research around Theravance Biopharma Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Pharmaceuticals companies with insider activity
Insider trading in North America